leisure time -WSS

leisure time

author：leisure time 2025-10-04 11:31:12 - browse：35

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

WSS

Intellia reports positive results for its CRISPR

Kaiser's Risant Health gobbled up Geisinger. Who is next?

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

See how much Covid

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

explore

Medicare proposal to cover medical devices draws a mixed reaction

CVS is willing to dump 10% of its Medicare Advantage members

In age of alternative facts, a scholarly course on calling out crap

FDA's Pazdur wants cancer trials to range beyond China alone

Guidelines to prevent youth baseball injuries need more muscle

Abbott's new stent may help patients with peripheral artery disease

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA's Pazdur wants cancer trials to range beyond China alone

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Kaiser's Risant Health gobbled up Geisinger. Who is next?

focus

NIH documents show early flaws of $1.6 billion long Covid program

ASCO: Palliative care found as helpful given virtually as in person

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

ASCO: Palliative care found as helpful given virtually as in person

Supreme Court to hear if Covid misinformation is protected speech

NIH documents show early flaws of $1.6 billion long Covid program

hotspot

leisure time

hotspot

entertainment